Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 16, 2008. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the SmithKline Beecham Mid-Term Incentive Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications rather than financial performance data.
Material Changes
There are no material changes to financial performance reported. The only change noted is an increase in share interests for specific individuals following the re-investment of dividends paid on April 10, 2008.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It strictly details compliance with Disclosure and Transparency Rule 3.1.4R(1)(a) regarding director transactions.
Key Facts for Investors
- Transaction Type: Re-investment of dividends into Ordinary share ADRs.
- Transaction Price: $43.84 per ADR.
- Participants: Dr. JP Garnier (2,602.78 shares), Mr. E J Gray (16.56 shares), and Mr. D J Phelan (501.10 shares).
- Notification Date: April 15, 2008.
- Dividend Date: April 10, 2008.